Jaguar Health (NASDAQ:JAGX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research report report published on Monday. The firm issued a sell rating on the biotechnology company’s stock.

Jaguar Health Stock Performance

Shares of NASDAQ:JAGX opened at $0.17 on Monday. The business’s fifty day moving average price is $0.09 and its two-hundred day moving average price is $0.18. The company has a current ratio of 2.00, a quick ratio of 1.34 and a debt-to-equity ratio of 6.33. Jaguar Health has a one year low of $0.05 and a one year high of $1.22.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.